Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination
详细信息 查看全文
- 作者：Jungoh Ham1 ; 11 ; Carlotta Costa4 ; 5 ; 11 ; Renata Sano2 ; Timothy L. Lochmann8 ; Erin M. Sennott4 ; 5 ; Neha U. Patel1 ; Anahita Dastur4 ; 5 ; Maria Gomez-Caraballo4 ; 5 ; Kateryna Krytska2 ; Aaron N. Hata4 ; 5 ; Konstantinos V. Floros1 ; Mark T. Hughes1 ; Charles T. Jakubik4 ; 5 ; Daniel A.R. Heisey1 ; Justin T. Ferrell1 ; Molly L. Bristol1 ; Ryan J. March4 ; 5 ; Craig Yates1 ; Mark A. Hicks1 ; Wataru Nakajima9 ; Madhu Gowda10 ; Brad E. Windle1 ; Mikhail G. Dozmorov6 ; Mathew J. Garnett7 ; Ultan McDermott7 ; Hisashi Harada1 ; Shirley M. Taylor8 ; Iain M. Morgan1 ; Cyril H. Benes4 ; 5 ; Jeffrey A. Engelman4 ; 5 ; Yael P. Mossé ; 2 ; 3 ; Anthony C. Faber1 ; acfaber@vcu.edu" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cancer Cell
- 出版年：2016
- 出版时间：8 February 2016
- 年：2016
- 卷：29
- 期：2
- 页码：159-172
- 全文大小：2891 K
文摘
- •
Amplified MYCN is synthetic lethal with the BCL-2 inhibitor ABT-199 in neuroblastoma
- •
MYCN upregulates the MCL-1 inhibitor, NOXA
- •
MYCN-amplified neuroblastomas are further sensitized to ABT-199 with MLN8237
- •
ABT-199 with MLN8237 induce tumor regressions in MYCN-amplified neuroblastoma mice